Dan Greenberg
גרינברג, דן, 1966-
Greenberg, Dan, 1966-
VIAF ID: 97865286 (Personal)
Permalink: http://viaf.org/viaf/97865286
Preferred Forms
- 100 0 _ ‡a Dan Greenberg
-
-
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Adoption and diffusion of technologies in Israeli medical centers in an era of budget constraints | |
The adoption of cost-effectiveness acceptability curves in cost-utility analyses | |
The association between adherence to cardiovascular medications and healthcare utilization | |
Can we afford to eliminate restenosis? Can we afford not to? | |
Can We Better Prioritize Resources for Cost-Utility Research? | |
The case for orthopaedic medicine in Israel | |
Clinical trials and health economics – A marriage of convenience or a marriage made in heaven? | |
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. | |
Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money? | |
Cost-Effectiveness Analysis Expands its Reach Worldwide | |
Cost-utility analyses of diagnostic laboratory tests: a systematic review | |
The costs and cost-effectiveness of an integrated sepsis treatment protocol | |
Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study | |
Decisions to adopt new technologies at the hospital level: insights from Israeli medical centers. | |
Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis | |
Determinants of Cost-Related Nonadherence to Medications among Chronically Ill Patients in Maccabi Healthcare Services, Israel | |
Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation | |
Do drug formulary policies reflect evidence of value? | |
Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions? | |
Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents | |
Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. | |
Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease | |
Effects of Activity-Based Hospital Payments in Israel: A Qualitative Evaluation Focusing on the Perspectives of Hospital Managers and Physicians | |
Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent. | |
Further Steps in the Development of Pharmacoeconomics, Outcomes Research, and Health Technology Assessment in Central and Eastern Europe, Western Asia, and Africa | |
Growth and quality of the cost-utility literature, 1976-2001. | |
Health-Related Utility Weights in a Cohort of Real-World Crohn's Disease Patients | |
High-Quality, Scientific Rigor, and Diversity: Value in Health Regional Issues Is Getting Its Impact | |
Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach | |
Implantable cardioverter defibrillators in Israel: utilization and implantation trends | |
In-hospital costs of self-expanding nitinol stent implantation versus balloon angioplasty in the femoropopliteal artery (the VascuCoil Trial). | |
Is burnout associated with referral rates among primary care physicians in community clinics? | |
Is the United States ready for QALYs? | |
Low-value services in value-based insurance design. | |
A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases | |
Normative data for the Brief Symptom Inventory for patients with Crohn's disease | |
Note from the Editors | |
Nutritional risk and health care use before and after an acute hospitalization among the elderly | |
Overuse of Head CT Examinations for the Investigation of Minor Head Trauma: Analysis of Contributing Factors. | |
Patient adherence: a blind spot in cost-effectiveness analyses? | |
PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them? | |
Peer review in publication: factors associated with the full-length publication of studies presented in abstract form at the annual meeting of the Society for Medical Decision Making | |
The process of updating the National List of Health Services in Israel: is it legitimate? Is it fair? | |
Quality of abstracts of papers reporting original cost-effectiveness analyses | |
Reimbursement policies, incentives and disincentives to perform laparoscopic surgery in Israel. | |
The Relation Between the Modified Rankin Scale (mRS) Scores and Utility Weights: Results from a Survey Among Community Dwelling Long Term Stroke Survivors | |
Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration | |
Rethinking cost-effectiveness in the era of zero healthcare spending growth. | |
Simple pain measures reveal psycho-social pathology in patients with Crohn's disease | |
A synthesis of cost-utility analysis literature in infectious disease | |
Temporal trends in patient characteristics and survival of intensive care admissions with sepsis: a multicenter analysis*. | |
Trends in the measurement of health utilities in published cost-utility analyses | |
Twenty years of cost-effectiveness analysis in medical imaging: are we improving? | |
Using Health State Classification Systems for Utility Elicitation in the Elderly | |
Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients. | |
What Are the Challenges in Conducting Cost-of-Illness Studies? | |
When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature | |
Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions. | |
Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study | |
אמוץ והטמעה של טכנולוגיות בבתי חולים בישראל | |
נתוח עלות מועילות של טפול בדפיברילטור אוטומטי משתל בחולים הסובלים מהפרעות קצב |